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Iron is an essential cofactor with unique redox
properties. Iron-regulatory proteins 1 and 2 (IRP1/2)
have been established as important regulators of
cellular iron homeostasis, but little is known about
the role of other pathways in this process. Here we
report that the mammalian target of rapamycin
(mTOR) regulates iron homeostasis by modulating
transferrin receptor 1 (TfR1) stability and altering
cellular iron flux. Mechanistic studies identify triste-
traprolin (TTP), a protein involved in anti-inflamma-
tory response, as the downstream target of mTOR
that binds to and enhances degradation of TfR1
mRNA. We also show that TTP is strongly induced
by iron chelation, promotes downregulation of iron-
requiring genes in both mammalian and yeast cells,
and modulates survival in low-iron states. Taken
together, our data uncover a link between metabolic,
inflammatory, and iron-regulatory pathways, and
point toward the existence of a yeast-like TTP-medi-
ated iron conservation program in mammals.
INTRODUCTION
Iron-deficiency anemia affects one quarter of the world’s popu-
lation (WHO, 2008), yet themechanisms of iron regulation remain
largely unexplored. Iron is an essential micronutrient required for
fundamental biological processes including oxygen delivery,
protein synthesis, DNA replication, and oxidative phosphoryla-
tion (Arredondo and Nu´n˜ez, 2005). However, the ability of iron
to easily gain and lose electrons also facilitates the production
of reactive oxygen species (ROS) by Fenton reaction (Aisen
et al., 2001). Thus, iron levels must be tightly controlled at both
cellular and systemic levels and deregulation of iron homeo-
stasis is associated with aging, metabolic disorders and cancer
(Aisen et al., 2001; Altamura and Muckenthaler, 2009; Torti and
Torti, 2011; Weinberg, 2010).
Maintenance of cellular iron homeostasis is dependent on
RNA-binding iron-regulatory proteins 1 and 2 (IRP1/2), which
are activated under iron-deficient conditions. IRP1/2 function
to restore iron levels through (1) stabilization of transferrinCell Mreceptor 1 (TfR1) messenger RNA (mRNA) and increased iron
uptake, (2) mobilization of cellular iron stores, and (3) reduction
in cellular iron export through the suppression of ferroportin 1
(Fpn1), the only cellular iron exporter identified to date (Hentze
et al., 2010; Rouault, 2006; Wang and Pantopoulos, 2011). Addi-
tionally, an iron conservation response has been recently
described in S. cerevisiae, where coordinated expression of
the tandem zinc finger (TZF) proteins Cth1p and Cth2p causes
destabilization of mRNAs of nonessential iron-containing
proteins and liberation of iron for use in vital processes (Pedro-
Segura et al., 2008; Puig et al., 2005, 2008). A mammalian
homolog of Cth1p/Cth2p, tristetraprolin (TTP), has been exten-
sively studied in the context of immunosuppression (Baou
et al., 2009), but its role in iron regulation is not known.
Mammalian target of rapamycin (mTOR) is an important
sensor of cellular energy state and a major hub for integration
of environmental cues (Howell and Manning, 2011; Sengupta
et al., 2010). The complex is activated under energetically favor-
able, low-stress states, while adverse conditions, such as star-
vation, cytotoxic insults and DNA damage, act to inhibit mTOR
signaling and promote survival through conservation of cellular
resources (Dunlop and Tee, 2009; Soliman, 2005). Many of the
processes governed by mTOR are dependent on iron as
a cofactor and would require a steady supply of this metal. There
appears to be a link between iron homeostasis and mTOR, as
clinical use of rapamycin is associated with the development of
microcytic anemia that is mechanistically distinct from the
anemia of chronic disease (Kim et al., 2006; Maiorano et al.,
2006; Sofroniadou et al., 2010). Here, we establish mTOR
pathway as a regulator of iron homeostasis that acts through
modulation of iron transporters and alteration of cellular iron
flux. Moreover, we identify TTP as a target of mTOR that, at least
in part, modulates its iron-regulatory effects through destabiliza-
tion of TfR1 mRNA.
RESULTS
mTOR Regulates Cellular Iron Homeostasis
mTOR activation stimulates several important anabolic pro-
cesses that depend on the presence of iron as a cofactor;
therefore, we hypothesized that mTOR may play a role in the
regulation of cellular iron availability and utilization. To test this,
we modulated mTOR signaling in wild-type (WT) mouse embry-
onic fibroblasts (MEFs) and H9c2 cardiac myoblasts followed byetabolism 16, 645–657, November 7, 2012 ª2012 Elsevier Inc. 645
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Figure 1. mTOR Regulates Cellular Iron
Content and Uptake
(A) mTOR modulation in MEFs (left) and H9c2
(right) cells assessed by western blot of phos-
phorylated S6 protein. Densitometry analysis is
shown below thewestern blot (n = 3). TSC2 protein
levels (right) in TSC2 KO-V and TSC2 KO-TSC2
MEFs are shown.
(B) Nonheme iron content in WTMEFs treated with
20 nM rapamycin for 48 hr normalized to protein
concentration (n = 12). All subsequent experi-
ments were carried out with 20 nM rapamycin
treatment for 48 hr in all mammalian cell lines,
unless noted otherwise.
(C) Nonheme iron content in TSC2 KO-V and TSC2
KO-TSC2 MEFs with or without rapamycin treat-
ment (n = 6–12).
(D) Radioactive iron uptake over 1 hr by WT MEFs
with rapamycin or vehicle control treatment
(n = 12).
(E) Radioactive iron uptake over 1 hr by TSC2
KO-V and TSC2 KO-TSC2 MEFs with or without
rapamycin (n = 6–12).
(F) Cellular content of 55Fe inWTMEFs treatedwith
rapamycin or vehicle control after the 24 hr incu-
bation with radioactive iron (n = 12).
(G) Cellular content of 55Fe in TSC2 KO-V and
TSC2 KO-TSC2 MEFs with or without rapamycin
after the 24 hr incubation with radioactive iron
(n = 6).
Data are presented as mean ± SEM. *p < 0.05
versus control, #p < 0.05 versus TSC2 KO-V
MEFs. See also Figure S1.
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Characterization of an Iron-Regulatory Pathwayquantification of heme and nonheme iron content. Rapamycin
effectively inhibited mTOR signaling in both cell lines (Figure 1A),
as assessed by the ablation of pS6 expression. Treatment with
rapamycin led to a significant increase in both nonheme and
heme iron content in MEFs (Figure 1B and Figure S1A available
online) and H9c2 cells (Figures S1B and S1C). Consistent with
elevation in iron levels, protein content of ferritin light chain, an
iron storage molecule, was also significantly increased by rapa-
mycin treatment in WT MEFs (Figure S1D). Increased heme
levels were likely due to inhibition of heme degradation, as the
mRNA levels of heme oxygenase 1 (HMOX1) were significantly
decreased, while the expression of key heme synthetic enzymes,646 Cell Metabolism 16, 645–657, November 7, 2012 ª2012 Elsevier Inc.d-aminolevulinic acid synthase 1 (ALAS1)
and ferrochelatase, remained unchanged
(Figure S1E). To activate mTOR, we used
TSC2 knockout MEFs in which the
upstream inhibitor of the pathway is
genetically deleted and pS6 levels are
increased (Figure 1A). The knockout
MEFs were transfected with either an
empty pEF6 vector (referred to as TSC2
KO-V MEFs) or with pEF6/TSC2 vector
to reconstitute TSC2 expression in the
knockout MEFs (TSC2 KO-TSC2 MEFs),
followed by selection with blasticidin to
generate stable transgenic cell lines as
described (Zhang et al., 2003). Constitu-tive activation of mTOR in TSC2 KO-V MEFs decreased heme
and nonheme iron, and rapamycin restored their levels to that
of control (Figures 1C and S1F), indicating that the observed
changes were due to mTOR modulation.
To determine whether changes in cellular iron resulted from
alterations in iron import, we measured the uptake of radioactive
iron (55Fe) after mTOR modulation. Unexpectedly, rapamycin
treatment significantly reduced iron uptake, while TSC2 KO-V
MEFs or TSC2 small interfering RNA (siRNA)-treated H9c2
myoblasts displayed enhancement of iron uptake after 60 min
of incubation (Figures 1D, 1E, S1G, and S1H). The differences
persisted even after 24 hr of growth with 55Fe in all cell lines
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Figure 2. mTOR Regulates Expression of
Iron Transporters
(A and B) Protein levels of TfR1 in WT MEFs (A) and
Fpn1 in mouse hearts (B) after rapamycin treat-
ment. Densitometry analyses are presented below
the western blots.
(C) mRNA levels of iron transporters, TfR1 and
Fpn1, as determined by qRT-PCR, in WT MEFs
with or without rapamycin treatment (n = 6–12).
(D) mRNA levels of iron transporters in TSC2 KO-V
and TSC2 KO-TSC2 MEFs with or without rapa-
mycin treatment (n = 6–12).
(E) mRNA levels of genes unrelated to iron
homeostasis inWTMEFs treatedwith rapamycin or
vehicle control (n = 6).
Data are presented as mean ± SEM. *p < 0.05
versus control, #p < 0.05 versus TSC2 KO-VMEFs.
See also Figure S2.
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Characterization of an Iron-Regulatory Pathway(Figures 1F, 1G, S1I, and S1J). These results suggest that
inhibition of mTOR results in cellular iron accumulation despite
reduction in iron uptake, while mTOR activation has the opposite
effect.
We next studied the mechanism for these observations by
measuring the expression of genes involved in iron regulation
in MEFs and H9c2 (Anderson and Vulpe, 2009; Hentze et al.,
2010). Consistent with the decreased iron uptake, rapamycin
significantly reduced the mRNA and protein levels of transferrin
receptor 1 (TfR1) required for the uptake of transferrin-bound
iron (Figures 2A and 2C). Additionally, TfR1 levels were reduced
in MEFs and H9c2 treated with Torin-1, a more specific inhibitor
of the mTOR pathway (Figure S2A). However, mRNA and protein
levels of an iron exporter, Fpn1, were also reduced by rapamycin
and Torin-1 (Figures 2B, 2C, and S2A). Consistently, mTOR acti-
vation increased the expression of TfR1 and Fpn1, while rapa-Cell Metabolism 16, 645–657,mycin suppressed this effect (Figure 2D).
These results suggest that mTOR inhibi-
tion leads to coordinated reduction in the
expression of TfR1 and Fpn1, resulting in
a net accumulation of cellular iron, while
mTOR activation has the opposite effect.
In addition to its effects on TfR1 and
Fpn1, rapamycin led to a global suppres-
sion of many iron-regulatory genes in
MEFs and H9c2, consistent with a reduc-
tion in cellular iron flux, while the opposite
was observed with activation of mTOR
(Figures S2B and S2E). On contrary, we
found no downregulation of several genes
not involved in regulation of cellular iron
upon rapamycin treatment of WT MEFs
(Figure 2E), suggesting that its effects on
iron-regulatory network are specific and
do not represent an artifact of a general-
ized transcriptional repression.
TfR1 Is a Target of mTOR
Concurrent decrease in the expression of
a protein mediating iron import (TfR1)and an iron exporter (Fpn1) by rapamycin raises two possibilities.
First, mTOR inhibition may negatively regulate the expression of
TfR1, leading to reduced iron import and net iron loss from the
cell. The resulting deficiency would activate IRP1/2 with subse-
quent inhibition of Fpn1 to prevent further iron loss (Figure S3A).
Alternatively, rapamycin may primarily target Fpn1, leading to
cellular iron accumulation due to decreased export. This would
suppress IRP1/2 activity and secondarily reduce TfR1 levels to
stop iron gain through the import (Figure S3B). To distinguish
between these two possibilities, we assessed the time course
of TfR1 and Fpn1 expression during the first 24 hr of rapamycin
treatment. We observed a steady decrease in TfR1 mRNA levels
with rapamycin, while Fpn1 expression was initially upregulated
at 2 and 4 hr, followed by a decline (Figure 3A). These findings
point toward the possibility of mTOR primarily regulating TfR1
expression, and the changes in Fpn1 being the secondary effectNovember 7, 2012 ª2012 Elsevier Inc. 647
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Figure 3. TTP Is Functionally Similar to Yeast Cth1p/2p
(A) Time course of TfR1 and Fpn1 mRNA regulation by rapamycin in WT MEFs over 24 hr (n = 12–18).
(B) TfR1mRNA stability inWTMEFswith andwithout rapamycin pretreatment as assessed by qRT-PCR after incubationwith transcriptional inhibitor actinomycin
D (act D), normalized to TfR1 mRNA levels at time point zero in each respective group (n = 3).
(C) IRP1 mRNA levels in IRP2 KO MEFs after treatment with IRP1 siRNA (n = 6).
(D) TfR1 mRNA levels in IRP1/2 KD/KO MEFs after rapamycin treatment (n = 6).
(E and F) TTP mRNA (E) and TTP protein (F) levels in WTMEFs after DFO treatment for 16 hr (n = 3–6). Densitometry analysis is presented below the western blot.
(G) TTP mRNA levels in H9c2 cells after 16 hr incubation with 2,2-BPD or FAC for iron chelation and overload, respectively (n = 6).
(H) mRNA levels of iron-containing proteins inWTMEFs treated with 150 mMDFO for 16 hr (n = 6). Unless noted otherwise, all subsequent studies were performed
wity this protocol for iron chelation with DFO.
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Characterization of an Iron-Regulatory Pathway(Figure S3A). Consequently, we focused our efforts on studying
the regulation of TfR1 by mTOR.
To uncover the mechanism by which mTOR regulates TfR1,
we first assessed the stability of TfR1 mRNA after rapamycin
treatment. Incubation of rapamycin-treated MEFs with a tran-
scriptional inhibitor actinomycin D led to a significant reduction
in TfR1 mRNA stability relative to the control group (Figure 3B),
suggestive of posttranscriptional regulation. The key known
posttranscriptional regulators of TfR1 are IRP1/2 proteins,
which, we hypothesized, may mediate the mTOR-dependent
changes in TfR1. To determine whether IRP1/2 pathway medi-
ates the suppression of TfR1 by rapamycin, we downregulated
IRP1 expression in IRP2 KO MEFs using an siRNA approach
(IRP1/2 KD/KOMEFs), which resulted in a significant knockdown
of IRP1 expression (Figure 3C) and a reduction in TfR1 mRNA,
consistent with a functional inhibition of the IRP1/2 pathway
(Figure S3C). However, the repression of TfR1 by rapamycin
was intact in the IRP1/2 KD/KO MEFs (Figure 3D), indicating
that regulation of TfR1 by mTOR is independent of the IRP1/2
pathway.
TTP Is Functionally Similar to Iron-Regulating Yeast
Cth1p/Cth2p Proteins
Recent studies in S. cerevisiae found TZF proteins, Cth1p and
Cth2p, to regulate cellular iron homeostasis by binding to
AU-rich elements (AREs) and destabilizing the mRNAs of iron-
requiring proteins, thus salvaging iron for use in essential func-
tions (Puig et al., 2005). Since we showed that IRP1/2 proteins
do not mediate the effects of mTOR on TfR1, we hypothesized
that TZF proteins may regulate TfR1 and cellular iron homeo-
stasis in mammals. Three TZF proteins with homology to
Cth1p and Cth2p, TTP (ZFP36), CMG1 (Zfp36l1), and TIS11D
(Zfp36l2), have been identified in mammals (Baou et al., 2009)
and studied in the context of cytokine signaling (Carrick et al.,
2004). To determine whether these proteins modulate iron
homeostasis similar to Cth1p/Cth2p in yeast, we first assessed
their regulation by cellular iron levels. Iron chelation with DFO
resulted in a significant and dose-dependent upregulation of
TTP mRNA (Figure 3E) and protein expression (Figure 3F).
Treatment with 2,2-bipyridyl (2,2-BPD), a lipophilic iron chelator
that is mechanistically distinct from DFO, also induced TTP
expression (Figure 3G), suggesting that the observed effect is
indeed due to a reduction in cellular iron and is not restricted
to DFO. Moreover, iron overload with ferric ammonium citrate
(FAC) suppressed TTP expression (Figure 3G). The mRNA levels
of the other two TZF proteins were also increased by DFO in
MEFs and H9c2 cells (Figures S3D and S3E); however, they
were excluded from subsequent studies due to the lack of regu-
lation by mTOR (Figures S3F and S3G). Taken together, our
results show that, similar to Cth1p/Cth2p in yeast, TTP is regu-
lated by cellular iron status in mammals.
To further confirm the functional similarity between Cth1p/
Cth2p and TTP, we studied the ability of TTP to reduce the
expression of ARE-containing iron-requiring proteins (ABCE1,(I) mRNA levels of iron-containing proteins in TTP WT and KO MEFs (n = 12–18).
(J) mRNA levels of iron-containing proteins in TTP KO and WT MEFs in the prese
(K) mRNA levels of iron-containing Cth2p targets in cth1Dcth2D yeast with ectop
Data are presented as mean ± SEM. *p < 0.05 versus control, #p < 0.05 versus c
Cell Ma Fe/S cluster protein involved in ribosome biogenesis and
Lias, lipoic acid synthase) (Figure S3H). Similar to yeast, iron
chelation reduced the expression of ABCE1 and Lias in WT
MEFs (Figure 3H) but did not suppress mRNA levels of most
other proteins that do not require iron for their function (Fig-
ure S3I). Moreover, mRNA levels of ABCE1 and Lias were
increased in TTP KO MEFs (Figures 3I and S3J), while ABCE1
levels were reduced by TTP overexpression inWTMEFs (Figures
S3J and S3K), confirming the inhibitory function of TTP. DFO
treatment of TTP KO MEFs not only failed to decrease, but
instead led to an exaggerated increase in the expression of
ABCE1 and Lias (Figure 3J), suggesting that TTP is critical for
the repression of iron-containing proteins by iron chelation.
Finally, to determine whether mammalian TTP can complement
the Cth1p/Cth2p deletion in yeast, we expressed the WT and
TZF mutant allele of human TTP (C124R) (Lai et al., 1999) under
the control of the iron-regulated CTH2 promoter in yeast cells.
Similar to MEFs, treatment of Cth1DCth2D yeast with an iron
chelator bathophenanthroline (BPS) led to an increase in the
mRNA levels of two known Cth1p/Cth2p targets, succinate
dehydrogenase subunit 4 (SDH4) and aconitase (ACO1), while
transfection of these cells with Cth2 plasmid restored the
suppression of iron-containing genes by iron deficiency (Fig-
ure 3K). Moreover, overexpression of WT human TTP, but not
the C124R construct, reduced the mRNA levels of SDH4 and
ACO1 under iron-limiting conditions, suggestive of a functional
conservation between yeast Cth1p/Cth2p and mammalian TTP
(Figure 3K). Taken together, our findings suggest that the role
of TTP in regulation of cellular iron homeostasis is similar to
that performed by yeast Cth1p/Cth2p, namely suppressing the
expression of iron-containing proteins and potentially optimizing
iron utilization in low-iron states.
mTOR Regulates TTP Expression
Next, we assessed whether mTOR regulates the expression of
TTP. Rapamycin treatment of MEFs and H9c2 cells induced
expression of TTP mRNA and protein (Figures 4A, 4B, and
S4A). Significant upregulation of TTP mRNA was also observed
in Torin-1 treated MEFs and H9c2 cells (Figures S4B and S4C).
TTP levels were suppressed by mTOR activation in TSC2
KO-V MEFs, and rapamycin reversed these effects (Figure 4C).
Moreover, rapamycin treatment of WT MEFs resulted in a
significant decrease in the levels and stability of TTP targets
ABCE1 and Lias, consistent with TTP induction (Figures S4D
and S4E). Treatment of cells with both rapamycin and DFO
led to a greater induction of TTP expression than either agent
alone (Figure S4F), suggesting an additive effect. Importantly,
the downstream effects of TTP and rapamycin on iron regulation
were independent of the inflammatory response, as we did
not detect TNFa mRNA expression in MEFs or H9c2 cells
(Figures S4G and S4H). Finally, to determine whether the
regulation of TZF proteins by mTOR is conserved between
eukaryotic organisms, we treated WT yeast strain with rapa-
mycin and observed a significant induction of Cth1 and Cth2nce and absence of DFO (n = 6–12).
ic expression of human wild-type and TZF mutant TTP.
ontrol at 180 min. See also Figure S3.
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Figure 4. mTOR Regulates TTP Expression
(A and B) TTP mRNA (A) and TTP protein (B) levels in WT MEFs treated with rapamycin (n = 6–8).
(C) TTP mRNA levels in TSC2 KO-V and TSC2 KO-TSC2 MEFs with and without rapamycin treatment (n = 6–12).
(D) Cth1 and Cth2 mRNA levels in WT yeast cells treated with 1 mg/ml rapamycin for 24 hr (n = 6).
(E and F) mRNA levels of TTP in ARNT KO MEFs treated with rapamycin (E) or DFO (F) (n = 15).
(G and H) TTP mRNA levels in IRP1/2 KD/KO MEFs treated with rapamycin (G) or DFO (H) (n = 6).
(I) TfR1 mRNA levels in TTP KO and control MEFs (n = 15).
(J) TfR1 mRNA levels in WT MEFs transfected with TTP- or GFP-containing (control) vectors (n = 6).
(K) TfR1 mRNA stability in TTP WT and KO MEFs treated with the transcriptional inhibitor act D (n = 6).
Data are presented as mean ± SEM. *p < 0.05 versus control. See also Figure S4.
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Figure 5. mTOR Regulates TfR1 through
TTP
(A) Schematic representation of TfR1-30UTR-Luc
construct with IREs indicated in white and putative
AREs in gray.
(B and C) Luciferase assay of TfR1-30 UTR activity
in WT MEFs overexpressing TTP (B) or TTP KO
and WT MEFs (C), normalized to renilla luciferase
(n = 6).
(D) mRNA levels of TfR1 in total RNA coprecipi-
tated with TTP and IgG (control) antibodies in
HEK293 cells. Four primer sets targeting different
regions near the 30 UTR of TfR1 gene were used in
the RNA coIP assay and normalized to 18S as an
internal control. Data are presented as the fold
enrichment over the IgG control (n = 3).
(E) mRNA levels of TfR1 in TTP WT and KO MEFs
treated with rapamycin or vehicle control (n = 12).
(F) mRNA levels of ABCE1 and Lias in TTPWT and
KO MEFs with and without rapamycin treatment
(n = 12).
(G) TfR1 mRNA stability after 3 hr incubation with
act D in WT and TTP KO MEFs in the presence or
absence of rapamycin. Data are presented as the
fold change over TfR1 mRNA levels at time point
zero in each respective group (n = 3–6).
(H) TfR1 mRNA levels in TTP WT and KO MEFs
with and without DFO treatment (n = 6).
(I) Cell death as assessed by propidium iodine (PI)
and Annexin V labeling and flow cytometry in TTP
WT and KO MEFs treated with 250 mM DFO or
250 mM 2,2-BPD for 40 hr and normalized to the
vehicle-treated control (n = 4).
(J) Cell death in TTP KO MEFs with or without
6 hr pretreatment with rapamycin incubated with
250 mM DFO or 250 mM 2,2-BPD for 40 hr with or
without rapamycin (n = 4).
Data are presented as mean ± SEM. *p < 0.05
versus control, #p < 0.05 versus rapamycin pre-
treated control group. Rapa, rapamycin. See also
Figure S5.
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Characterization of an Iron-Regulatory PathwaymRNA (Figure 4D), consistent with our observations in the
mammalian cells.
Since both mTOR and cellular iron status are known to regu-
late hypoxia-inducible factor (HIF) signaling, we assessed TTP
regulation in aryl hydrocarbon receptor nuclear translocator
(ARNT) KO MEFs that lack the obligate binding partner of
HIF1a and HIF2a, thus disrupting HIF pathway (Patel and Simon,
2008). We found TTP levels to be increased both with DFO and
rapamycin treatment in ARNTKOMEFs (Figures 4E and 4F), indi-
cating that the observed regulation is HIF independent. More-
over, we observed significant induction of TTP expression in
IRP1/2 KD/KO MEFs (Figures 4G and 4H), suggesting that the
activity of IRP1/2 system does not mediate the upregulation of
TTP expression by rapamycin and DFO. In summary, we found
TTP to be negatively regulated by mTOR pathway in a HIF-
and IRP1/2-independent manner.
TTP Associates with and Regulates TfR1 mRNA
Since TTP modulates cellular iron homeostasis and is a down-
stream target of mTOR, we hypothesized that TTP may regulate
TfR1. Computational analysis of the 30 untranslated region (UTR)Cell Mof TfR1 revealed multiple putative AREs, some of which were
found in a close proximity to or overlapped with IREs (Fig-
ure S5A). Consistently, we found TfR1 mRNA levels to be
increased in TTP KO MEFs (Figure 4I) and with TTP siRNA in
H9c2 cells (Figure S5B), while TTP overexpression reduced
TfR1 levels in MEFs (Figure 4J). Moreover, TfR1 mRNA was
significantly stabilized in TTP KOMEFs in the presence of actino-
mycin D (Figure 4K), confirming that TTP regulates TfR1 expres-
sion on the level of mRNA stability.
To determine whether TTP regulates TfR1mRNA on its 30UTR,
we cloned the full-length 30UTR of mouse TfR1 downstream of
the firefly luciferase gene (TfR1-30UTR-Luc, Figure 5A) and
used renilla luciferase construct to normalize for transfection effi-
ciency. Consistent with TTP suppression of TfR1 on its 30UTR,
transfection of the TfR1-30UTR-Luc construct into WT MEFs
overexpressing TTP led to a significant reduction in the lumines-
cence signal (Figure 5B), while luminescence was increased in
TTP KO MEFs (Figure 5C).
Finally, to assess the interaction between TTP and TfR1
mRNA, we performed an RNA coimmunoprecipitation (RNA
coIP) experiment using the anti-TTP or control IgG antibody asetabolism 16, 645–657, November 7, 2012 ª2012 Elsevier Inc. 651
Table 1. Interaction between TTP and TfR1 mRNA
Gene
Relative
Expression, IgG
Relative
Expression, TTP
Fold Enrichment
Over IgG Control
Transferrin Receptor
TfR1-1 281.81 426.31 1.51
TfR1-2 528.61 672.54 1.27
TfR1-3 268.16 381.56 1.42
TfR1-4 266.13 369.66 1.45
Positive Controls
VEGF-1 1,931.18 3,678.42 1.90
VEGF-2 2,048.95 3,982.25 1.94
Pitx2-1 2,082.60 1,960.18 0.94
Pitx2-2 690.53 984.72 1.43
Negative Controls
b2MG 22,080.25 19,099.78 0.87
Fpn1 836.35 828.85 0.99
HPRT 39,322.53 34,227.51 0.87
18S 52.92 55.49 1.04
A RNA coIP experiment using a specific TTP antibody or control IgG anti-
body as bait establishes physical interaction between TTP and TfR1
mRNA. Four distinct sets of primers were designed to target regions of
TfR1 mRNA adjacent to its 30 UTR. Relative mRNA levels were assessed
by qRT-PCR and are displayed as the fold enrichment over IgG control.
VEGF1 and Pitx-2 are used as positive controls, and b2-microglobulin,
Fpn1, HPRT, and 18S rRNA are used as negative controls. See also
Figure S6.
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as described previously (Emmons et al., 2008). Since the mono-
clonal antibody used in the studies was raised against human
TTP, the pull-down experiments were performed in human
HEK293 cells. We designed four distinct primer sets for TfR1
to target regions near its 30UTR, and two primer sets for each
of the positive controls. We observed enrichment in the known
targets of TTP (VEGF [Essafi-Benkhadir et al., 2007] and Pitx-2
[Briata et al., 2003]) in the TTP antibody group compared to the
IgG, while no enrichment was observed for any of the negative
controls tested (Table 1). TfR1 mRNA levels were significantly
enriched in the TTP group compared to the IgG control (Table
1 and Figure 5D), indicative of an interaction between TTP and
TfR1 mRNA. Taken together, our results show that TTP is
induced by rapamycin and regulates TfR1 expression at the
posttranscriptional level.
mTOR Regulates Iron Homeostasis through TTP
Finally, we asked whether TTP mediates the changes in TfR1
expression observed with mTOR modulation. TTP KO MEFs
were incubated with rapamycin, and the expression of TfR1
was assessed. In the TTP WT MEFs, rapamycin led to the
expected 50% decrease in TfR1 levels; however, in TTP KO
MEFs, the reduction in TfR1 expression was significantly blunted
(Figure 5E). Furthermore, while the expression of ARE-containing
iron-requiring proteins was reduced by rapamycin in WT MEFs,
this response was greatly attenuated in TTP KO MEFs (Fig-
ure 5F). Finally, TfR1 mRNA stability was reduced in WT MEFs
incubated with rapamycin but not in TTP KO MEFs (Figure 5G).
These results establish TTP as the downstream target of652 Cell Metabolism 16, 645–657, November 7, 2012 ª2012 ElseviermTOR, whose activity is at least partially responsible for the
mTOR-dependent regulation of TfR1.
While we have shown that TTP regulates TfR1 mRNA stability,
the significance of TfR1 downregulation in the setting of iron defi-
ciency and in respect to the IRP1/2 pathway is unclear. We
hypothesized that TTP acts as a ‘‘brake’’ on the IRP1/2 system
to prevent the unnecessary overactivation of iron uptake as the
cell is reducing its iron use through TTP-dependent downregula-
tion of iron-containing proteins. If correct, this hypothesis
predicts exaggerated induction of TfR1 by iron deficiency in
the absence of TTP, while higher levels of TTP would blunt the
TfR1 upregulation by iron chelation. Consistently, we found
that the degree of TfR1 upregulation was significantly greater
in DFO-treated TTP KO MEFs compared to the chelated TTP
WTMEFs (Figure 5H), and a combination of DFO and rapamycin,
which had an additive effect on TTP upregulation (Figure S4F),
led to attenuation of TfR1 induction compared to DFO alone
(Figure S5C).
To assess the functional importance of TTP in regulation of
cellular iron, we measured the survival of TTP KO MEFs in iron-
deficient conditions. We hypothesized that TTP is protective in
low iron states, and thus its deletion will result in increased cell
death upon iron chelation. Consistently, we observed a signifi-
cant drop in cell viability of TTP KO MEFs treated with 250 mM
DFO and 250 mM 2,2-BPD for 40 hr (Figure 5I). In addition, TTP
KO MEFs were exquisitely sensitive to serum deprivation (Fig-
ure S5D), which is the main source of iron in the growth medium
(Kakuta et al., 1997), but not to glutamine deprivation (Fig-
ure S5D), indicative of tolerance of TTP KO MEFs to general
cellar stressors. Supplementation of TTP KO MEFs with trans-
ferrin-bound iron has significantly, although not completely,
reversed the effects of serum deprivation on cell viability, but
had no effect on viability of TTPKOMEFs grown in serum-replete
medium (Figure S5E). These findings suggest that TTP KOMEFs
have reduced cell viability when deprived of iron compared to
TTP WT MEFs.
To determine whether cell death in iron-deficient TTP KO
MEFs is mediated by mTOR pathway, we pretreated TTP KO
MEFs with rapamycin for 6 hr, followed by coincubation with
DFO and 2,2-BPD. Surprisingly, rapamycin has significantly
attenuated cell death due to iron chelation (Figure 5J). Analysis
of cell-cycle progression has revealed higher baseline division
rates in TTP KO MEFs compared to TTP WT MEFs (Figure S5F),
and a defect in cell-cycle arrest in response to DFO (Figures S5G
and S5H). On the other hand, pretreatment of TTP KOMEFs with
rapamycin prior to chelation with DFO has equally suppressed
cell-cycle progression in TTP KO and TTP WT MEFs (Figures
S5G and S5H), suggesting that rapamycin-dependent preserva-
tion of viability of TTP KO MEFs is due to the suppression of cell
division in TTP KO MEFs.
In summary, our results suggest that mTOR regulates cellular
iron homeostasis and TfR1 expression through TTP and its inhi-
bition may function as a negative feedback loop to fine-tune the
iron-deficiency response and maintain cell viability in low-iron
states.
mTOR and TTP Regulate Iron Homeostasis In Vivo
So far, our data suggest that mTOR and TTP regulate expression
of TfR1 and iron homeostasis in MEFs and H9c2 cells. ToInc.
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Figure 6. In Vivo Regulation of Iron Homeo-
stasis by mTOR and TTP
(A and B) Nonheme (A) and heme (B) iron levels
in the hearts of c57 black WT mice treated with
five daily intraperitoneal injections of rapamycin,
10mg/kg (n = 6), or equal volume of DMSOvehicle.
(C) TfR1 and Fpn1 mRNA levels in the hearts of
rapamycin-treated mice (n = 6).
(D) Western blot analysis of rapamycin-treated
mouse hearts. Densitometry analysis is presented
below the western blots (n = 3).
(E) Western blot analysis of TfR1 protein in the
hearts of TTP/TNFR1/2 KO (designated as TTP
KO) and matched littermate WT control mice
(designated as TTP WT). Densitometry analysis is
presented on the right of the western blot (n = 3).
(F) Nonheme iron levels in the hearts of TTP KO
and WT mice (n = 4).
(G) Western blot analysis of ferritin light and heavy
chains (FtL + FtH) and Fpn1 proteins in the hearts
of TTP KO and WT mice. Densitometry analysis is
presented below the western blots (n = 4).
(H) Model of cellular iron regulation by mTOR
and TTP.
Data are presented as mean ± SEM. *p < 0.05. See
also Figure S6.
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iron homeostasis in vivo, we treated c57 black WT mice with
five daily intraperitoneal injections of rapamycin to inhibit
mTOR, and also studied iron regulation in triple TTP and TNFa
receptors 1 and 2 knockout (TTP/TNFR1/2 KO) mice. While
mice with the deletion of TTP alone display profound inflamma-
tion primarily due to stabilization of TNFa (Taylor et al., 1996),
TTP/TNFR1/2 triple-KO mice show no inflammatory phenotype
for up to 1 year of age (Carballo and Blackshear, 2001) and
thus represent a suitable model to study iron regulation. Treat-
ment of WT mice intraperitoneally with rapamycin successfully
inhibited mTOR signaling, as evidenced by the absence of pS6
expression (Figure S6A). Similar to the in vitro findings, nonheme
and heme iron levels were increased (Figures 6A and 6B),
while the expression of TfR1 and Fpn1 was reduced (Figures
6C and 6D), in the hearts of rapamycin-treated mice. TTP
expression was also induced by rapamycin in the mouse hearts
(Figure 6D), suggesting that this protein may potentially mediate
TfR1 expression in vivo. Surprisingly, assessment of rapamycinCell Metabolism 16, 645–657,effects on hepatic iron homeostasis re-
vealed reduced nonheme iron levels (Fig-
ure S6B) with a decrease in TfR1, but
preservation of Fpn1 expression (Figures
S6C and S6D). This suggests that rapa-
mycin primarily reduces the uptake of
iron into the liver, leading to an export-
dependent iron loss. Finally, rapamycin
had no effect on the expression of
systemic iron-regulatory hormone hepci-
din and two of its upstream regulators,
bone morphogenic protein 6 (BMP6)
and hemojuvelin (HJV) (Figure S6E). Thus,rapamycin appears to primarily affect iron regulation on a cellular
level both in vitro and in vivo.
We next assessed the effects of TTP deletion on iron
regulation in TTP/TNFR1/2 KO and WT littermate control mice.
Consistent with our in vitro findings, TfR1 protein levels were
significantly induced in TTP-deficient mouse hearts (Figure 6E),
which corresponded to an increase in cardiac nonheme iron
content (Figure 6F) and elevated levels of iron storage protein
ferritin (light and heavy chains) (Figure 6G). However, there was
a reduction in the levels of Fpn1 protein with TTP deletion (Fig-
ure 6G). Analysis of iron homeostasis in TTP-deficient livers
revealed no significant change in nonheme iron content (Fig-
ure S6F), TfR1or ferritin light chain protein (Figure S6G), while,
similar to the heart, Fpn1 protein expression was suppressed.
To determine whether the suppression of Fpn1 protein was
due to increased expression and subsequent degradation by
hepcidin, wemeasured the levels of this peptide in TTP-deficient
mouse livers. However, consistent with the unaltered hepatic
iron levels, the protein content of hepcidin was similar inNovember 7, 2012 ª2012 Elsevier Inc. 653
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different mechanism for Fpn1 downregulation in the heart and
liver. Taken together, our data show that both mTOR and TTP
regulate TfR1 and iron homeostasis in vitro and in vivo, thus
providing an iron-regulatory pathway that likely complements
cellular functions of IRP1/2.
DISCUSSION
Iron is essential for the catalysis of many reactions and there
appears to be an intimate link between iron and energy metabo-
lism. Short-term iron deficiency is known to promote insulin
sensitivity, while iron overload may lead to glucose intolerance
(Dongiovanni et al., 2008; Liu et al., 2009). Iron accumulation is
also linked to nonalcoholic fatty liver disease and may cause
alteration in the function of adipocytes and their ability to oxidize
glucose (Dongiovanni et al., 2011). On a cellular level, circum-
stantial evidence points toward a crosstalk between energy
sensing and iron-regulatory pathways, as exemplified by a study
by Galvez et al. that identified mTOR as a positive regulator of
transferrin-bound iron uptake (Galvez et al., 2007), while iron
deficiency was shown to inhibit mTOR signaling (Ndong et al.,
2009; Ohyashiki et al., 2009). However, the direct and systematic
studies of mTOR and iron regulation are lacking. Here, we
describe a pathway that links mTOR, a major metabolic hub of
the cell, to regulation of cellular iron uptake and flux via the
modulation of TfR1 expression. Themechanism for the observed
changes is at least partially mediated by the TZF protein TTP,
which is induced by rapamycin, interacts with TfR1 mRNA and
leads to its degradation (Figure 6H). Moreover, we provide
evidence that TTP functions in mammals are similar to those of
yeast Cth1p/Cth2p in regulating cellular iron through a reduction
in the levels of iron-containing proteins and preservation of cell
viability in iron deficiency.
While it is possible that in vitro changes in cellular iron content
with mTOR modulation can be solely explained by differential
rates of cellular division and ‘‘iron-dilution’’ effect, the increased
iron levels in rapamycin-treated terminally differentiated mouse
hearts argue against this possibility. Moreover, the repressive
effects of rapamycin on genes involved in cellular iron regulation
are specific to this pathway and are not due to global transcrip-
tional inhibition, as we found the levels of iron-independent
genes either unaltered or even increased with rapamycin treat-
ment. The magnitude of change in iron levels with mTOR modu-
lation is modest, suggesting that mTOR may fine-tune cellular
iron utilization to match the metabolic requirements of a cell.
Alternatively, the modest change in iron with mTOR inhibition is
in agreement with our hypothesis that TTP is involved in iron
conservation response. While IRP1/2 activation enhances
cellular iron uptake and reduces export leading to iron accumu-
lation, TTP primarily affects the distribution of iron molecules
already present in the cell without a large induction of iron import
or storage. The exact role of TTP in regulation of iron homeo-
stasis under various environmental conditions remains to be
determined; however, our data highlight the importance of this
pathway in low-iron states, as evidenced by the severe loss of
cell viability in iron deficiency with TTP knockout.
The fact that TTP reduces TfR1 mRNA levels and stability is
surprising. We show that TTP is strongly induced by low iron654 Cell Metabolism 16, 645–657, November 7, 2012 ª2012 Elsevierlevels in two different cell lines and mouse hearts, and also
with mechanistically distinct chelators. Thus, it appears to be
counterintuitive that TTP signals to degrade TfR1 message while
IRP1/2 concurrently stabilize this mRNA. A similar situation
was described in yeast cells where Aft1p (the yeast homolog of
IRP1/2) activates the transcription of FIT1 and FIT2 genes
involved in iron uptake, whereas Cth2p promotes their degrada-
tion in response to iron deficiency (Puig et al., 2005). We hypoth-
esize that a parallel activation of the two pathways serves to
fine-tune TfR1 levels based on the severity of iron deficiency
and the degree of a reduction in cellular iron utilization by TTP.
As levels of iron-containing proteins decrease and more iron
becomes available, the need for additional import of iron
may go down, corresponding to a reduction in TfR1 levels.
In other words, TTP may act as a ‘‘brake’’ on the IRP1/2
response to better match the rate of iron import with the actual
needs of the cell and spare exogenous iron for use by other
tissues. The relative contribution of TTP and IRP1/2 pathways
to iron-deficiency response remains to be determined; however,
a significant sequence overlap between AREs and IREs, the
binding sites for TTP and IRP1/2, respectively, suggests a
possibility of steric hindrance effects. Moreover, the rapid
activation of IRP1/2 and slower transcriptional induction of TTP
by iron deficiency may provide an additional degree of regula-
tion, with IRP1/2 system serving as a rapid response aimed at
correcting iron deficiency by enhancing iron uptake. If unsuc-
cessful, the TTP-mediated iron-conservation program will
subsequently get induced, allowing cells to survive in chronic
iron deficiency.
In addition to TTP, our data suggest the existence of another,
yet unidentified, pathway mediating the mTOR-dependent
changes in iron homeostasis. First, we observed a significant
attenuation, but not a complete reversal, of rapamycin effects
in TTP KO MEFs. Second, rapamycin administration caused
a very rapid and progressive reduction in TfR1 mRNA levels,
reaching significance at four hours of treatment (n = 18). Since
the induction of TTP by rapamycin represents a later-stage
response, a more acute mechanism, such as phosphorylation
event or microRNA processing, may explain these findings.
Moreover, it is presently unclear how TTP expression is regu-
lated by mTOR. We found that induction of TTP by rapamycin
is unaltered in MEFs with defective HIF or IRP1/2 signaling,
suggesting that these pathways are not involved in mTOR-
dependent regulation of TTP. It is also unlikely that rapamycin
regulates TTP levels indirectly through an increase in cellular
iron levels, since rapamycin and iron chelation with DFO have
an additive, rather than an opposing, effect on TTP induction.
Thus, other pathways downstream of mTOR may play a role in
the regulation of TTP and cellular iron homeostasis. Moreover,
our data do not exclude a possibility of independent roles for
the mTOR and TTP pathways in regulation of TfR1 and iron
homeostasis. Extensive characterization of molecular networks,
environmental signals and downstream effectors of these path-
ways will shed light on their biological role in iron regulation.
In summary, we identified mTOR and TTP as players in cellular
iron homeostasis that regulate mRNA stability of TfR1 and
iron-containing genes. Moreover, we described the existence
of a Cth1p/Cth2p-like pathway in mammalian cells which may
represent an important iron-deficiency response mechanismInc.
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tory system.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
MEFs were grown in complete DMEM (Cellgro, VA) supplemented with 10%
FBS (Invitrogen, CA) and 1% penicillin-streptomycin (P/S). For glutamine-
deprivation experiments, Cellgro DMEM without L-glutamine (catalog number
15-013-CV) was used. Each of the genetically modified MEF lines was
compared to the matchedWTMEFs obtained from a littermate control mouse.
TSC2 KO-V and TSC2 KO-TSC2 MEFs were described previously (Zhang
et al., 2003). TTP KO (line 66) and TTP WT (line 67) MEFs were derived from
littermate E14.5 embryos as described (Taylor et al., 1996). ARNT KO MEFs
were a generous gift of Dr. Celeste Simon (Maltepe et al., 1997). IRP1 KO
and IRP2 KO MEFs were kindly provided by Dr. Tracey A. Rouault. H9c2
cardiac myoblasts were purchased from ATCC and kept in complete DMEM
(ATCC, VA) with 10% FBS and 1% P/S. H9c2 and MEF cells were treated
with 20 nM rapamycin (LC Labs, MA) for 24 or 48 hr, 150 mM DFO, or
200 mM 2,2-BPD for 16–24 hr unless specifically noted and 50 mg/ml FAC
(Sigma-Aldrich) for 16 hr.
siRNA Treatment
H9c2 cells were transfected with siRNA with DharmaFect (Thermo Scientific,
CO) reagent according to the manufacturer’s protocol. Rat TSC2 siGENOME
siRNA (Thermo Scientific) and rat TTP FlexiTube siRNA (QIAGEN, CA) were
used.
Quantitiative RT-PCR
RNAwas isolated with RNA STAT-60 (TEL-TEST, TX), reverse transcribed with
a Random Hexamer (Applied Biosystems, CA), and amplified on a 7500 Fast
Real-Time PCR system with SYBR Green PCR Master Mix (Applied Bio-
systems). Primers were designed with Primer3 (v. 0.4.0) software to target
sequences spanning an exon-intron-exon boundary. mRNA levels were calcu-
lated by the comparative threshold cycle method and normalized to b-actin
and/or HPRT gene.
Western Blot
Protein (15–30 mg) was resolved on SDS-PAGE gels and transferred to nitro-
cellulose membranes (Invitrogen, CA) which were probed with antibodies
against pS6 (Cell Signaling, MA), TfR1 (Invitrogen), Slc40A1 (Fpn1, Novus
Biologicals, CO), TTP (Cao et al., 2004), Hepcidin (Abcam, MA), FtL (Abcam),
FtL + FtH (Sigma-Aldrich), and Tubulin (Abcam). HRP-conjugated donkey
anti-rabbit and donkey anti-mouse were used as secondary antibodies
(Santa Cruz, CA) and visualized by Pierce SuperSignal Chemiluminescent
Substrates.
Plasmid Transfections
Plasmids were transfected into MEFs with Lipofectamine reagent (Invitrogen)
in OptiMEM (Cellgro) for 4 hr, followed by incubation in complete, antibiotic-
free medium for another 20 hr.
Nonheme and Heme Iron Assays
Nonheme iron was measured as described (Rebouche et al., 2004). In brief,
equal amounts of protein were mixed with protein precipitation solution
(1:1 1 N HCl and 10% trichloroacetic acid) and heated to 95C for 1 hr to
release iron. Precipitated protein was removed by centrifugation at 4C at
16,000 3 g for 10 min, the supernatant was mixed with the equal volume of
chromogen solution (0.5 mM ferrozine, 1.5 M sodium acetate, 0.1% [v/v]
thioglycolic acid), and the absorbance was measured on a Spectra Max
Plus microplate reader at 562 nm. Heme was quantified as described (Ward
et al., 1984). In brief, equal amounts of protein were mixed with 2 M oxalic
acid and were heated to 95C for 30 min to release iron from heme and
generate protoporphyrin IX. Samples were then centrifuged for 10 min at
1,000 3 g at 4C to remove debris, and the fluorescence of the supernatant
was assessed at 405 nm/600 nm on Spectra Max Gemini fluorescence micro-
plate reader.Cell M55Fe Uptake Studies
55Fe (Perkin-Elmer, MA) was conjugated to nitriloacetic acid (NTA, Sigma-
Aldrich) and dissolved to the final concentration of 100–300 nM in complete,
serum-containing medium 24 hr prior to the beginning of the experiments.
MEFs and H9c2 were incubated for 1 hr or 24 hr in the 55Fe-containing
complete medium, washed three times with ice-cold 500 mM BPS in PBS to
remove the membrane-associated 55Fe, and lysed with 1% Triton X-100 in
TBS. The radioactivity of each sample was determined on Beckman scintilla-
tion counter and normalized to the protein content of each sample.
mRNA Stability Assay
MEFs were incubated in the complete medium supplemented with 5 mM acti-
nomycin D (Sigma-Aldrich) for 3–6 hr. No drop in cell viability was observed at
the end of the treatment. RNA was collected and mRNA levels were analyzed
by qRT-PCR as described above.
RNA CoIP
The protocol was adapted from Emmons et al. (2008) with the following modi-
fications. HEK293 cells were resuspended in buffer A (10mMTris-HCl [pH 7.6],
1 mM KAc, 1.5 mM MgAc, 2 mM DTT, 10 ml/ml ProteaseArrest inhibitors) and
lysed with a Power Gen 500 homogenizer (Fisher Scientific, PA), followed by
centrifugation at 12,000 3 g for 10 min at 4C to remove debris. Protein G
Sepharose Fast Flow beads (Sigma-Aldrich) were incubated with human
TTP (kindly provided by Dr. William Rigby, Dartmouth University) or IgG anti-
body in the IP buffer (10 mM Tris-HCl [pH 7.6], 1.5 mM MgCl2, 100 mM
NaCl, 0.5%Triton X-100, 10 ml/ml ProteaseArrest inhibitors) at 4Cwith contin-
uous rotation for 4 hr. Beads were then washed six times with cold IP buffer
and incubated with HEK293 lysate at 4C with continuous rotation for 2 hr.
RNA was collected, and equal amounts were amplified by qRT-PCR. Expres-
sion of each gene was normalized to that of 18S, and data were expressed as
the fold enrichment over IgG control.
Luciferase Assay
Luciferase assay of TfR1-30UTR-Luc was performed with the Dual Glo Lucif-
erase Assay system (Promega) according to the manufacturer’s protocol.
The 30 UTR of TfR1 was cloned into the pMIR-report vector containing the
gene for firefly luciferase (Ambion) and confirmed by sequencing. The lumines-
cence was quantified on a Berthold Technologies Luminometer (Germany),
and the Dual-Glo Stop & Glo reagent was added to quench firefly lumines-
cence and provide substrate for renilla luminescence that was used to
normalize for transfection efficiency.
Cell Death Studies
Cell death was assessed by labeling with propidium iodine (PI) (Sigma-Aldrich)
and/or Alexa Fluor 350-conjugated Annexin V (Molecular Probes, NY) and was
analyzed by flow cytometry in a FacsCanto flow cytometer (BD Biosciences).
For cell-cycle studies, cells were incubated with rapamycin for 6 hr and coin-
cubated with DFO and rapamycin for 10 hr prior to collection. Cells were then
collected by trypsinization, washed, and fixed in 70% ethanol at 20C
for 2 hr, followed by incubation in the PI staining solution (50 mg/ml PI,
0.2 mg/ml RNase A, 0.1% Triton X-100 in PBS) at 37C for 20 min. The cell
cycle was then analyzed by flow cytometry and FlowJo 7.6 software.
Mouse Studies
Wild-type C57BL/6 females were purchased from Jackson Labs and treated
with five daily intraperitoneal injections of rapamycin at 10 mg/kg or DMSO.
Mice were then anesthetized with 250 mg/kg dose of freshly prepared
Tribromoethanol (Avertin), and the harvested organs were flash frozen in liquid
nitrogen. The animal studies were conducted in accordance with North-
western University animal care guidelines.
Yeast Studies
Yeast cth1Dcth2D cells transformed with pRS416 vector alone or expressing
CTH2, TTP, or TTP-C124R under the control of CTH2 promoter region were
grown in synthetic media containing 300 mM iron (+Fe) or 100 mM of the
Fe2+-specific chelator bathophenanthroline disulfonic acid (–Fe), and RNA
was extracted and analyzed by RNA blotting as previously described (Puig
et al., 2005). Actin (ACT1) mRNA levels were used as a loading control.etabolism 16, 645–657, November 7, 2012 ª2012 Elsevier Inc. 655
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rapamycin for 16 hr, after whichmRNAwas collected and expression of Cth1/2
genes was analyzed by qRT-PCR.
Statistical Analysis
Data are expressed as mean ± SEM. Statistical significance was assessed
with the unpaired Student’s t test; a p value of less than 0.05 was considered
statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and can be found with this
article online at http://dx.doi.org/10.1016/j.cmet.2012.10.001.
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